Should I buy or sell Sol-Gel Technologies stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" SLGL shares. View SLGL analyst ratings or view top-rated stocks .

What is Sol-Gel Technologies' stock price target for 2024?

2 Wall Street analysts have issued 1-year price objectives for Sol-Gel Technologies' shares. Their SLGL share price targets range from $7.00 to $9.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 566.7% from the stock's current price. View analysts price targets for SLGL or view top-rated stocks among Wall Street analysts .

How have SLGL shares performed in 2023?

Sol-Gel Technologies' stock was trading at $4.5599 at the beginning of 2023. Since then, SLGL stock has decreased by 73.7% and is now trading at $1.20. View the best growth stocks for 2023 here .

When is Sol-Gel Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024. View our SLGL earnings forecast .

How were Sol-Gel Technologies' earnings last quarter?

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) released its quarterly earnings results on Thursday, November, 9th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. The company earned $0.21 million during the quarter, compared to the consensus estimate of $0.70 million. Sol-Gel Technologies had a negative net margin of 1,665.41% and a negative trailing twelve-month return on equity of 62.42%.

What other stocks do shareholders of Sol-Gel Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sol-Gel Technologies investors own include NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Flexion Therapeutics (FLXN) , Iovance Biotherapeutics (IOVA) , Marker Therapeutics (MRKR) , Teva Pharmaceutical Industries (TEVA) , Viking Therapeutics (VKTX) , Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP) .

When did Sol-Gel Technologies IPO?

(SLGL) raised $60 million in an initial public offering on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Jefferies and BMO Capital Markets served as the underwriters for the IPO and JMP Securities and Raymond James were co-managers.

Who are Sol-Gel Technologies' major shareholders?

Sol-Gel Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.23%), Yelin Lapidot Holdings Management Ltd. (0.99%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Sol-Gel Technologies?

Shares of SLGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Sol-Gel Technologies Stock Price, News & Analysis (NASDAQ:SLGL)

$1.20

+0.03 (+2.56%)

(As of 12/8/2023 ET)

Compare

Today's Range: $1.17
▼
$1.22
50-Day Range: $1.19
▼
$1.60
52-Week Range: $1.14
▼
$5.71

Volume: 18,716 shs
Average Volume: 13,332 shs
Market Capitalization: $27.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Sol-Gel Technologies MarketRank™ Stock Analysis

Analyst Rating: Strong Buy
3.50 Rating Score
Upside/Downside: 566.7% Upside
$8.00 Price Target
Short Interest: Bearish
0.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.01) to ($0.69) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

462nd out of 954 stocks

Pharmaceutical Preparations Industry

159th out of 362 stocks

3.8

Analyst's Opinion

Consensus Rating
Sol-Gel Technologies has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Sol-Gel Technologies has a forecasted upside of 566.7% from its current price of $1.20.
Amount of Analyst Coverage
Sol-Gel Technologies has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.64% of the float of Sol-Gel Technologies has been sold short.
Short Interest Ratio / Days to Cover
Sol-Gel Technologies has a short interest ratio ("days to cover") of 9.4.
Change versus previous month
Short interest in Sol-Gel Technologies has recently increased by 12.98%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Sol-Gel Technologies does not currently pay a dividend.
Dividend Growth
Sol-Gel Technologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SLGL.

1.1

News and Social Media Coverage

Search Interest
2 people have searched for SLGL on MarketBeat in the last 30 days.
MarketBeat Follows
7 people have added Sol-Gel Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sol-Gel Technologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
66.51% of the stock of Sol-Gel Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 34.10% of the stock of Sol-Gel Technologies is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Sol-Gel Technologies are expected to grow in the coming year, from ($1.01) to ($0.69) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sol-Gel Technologies is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sol-Gel Technologies is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sol-Gel Technologies has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sol-Gel Technologies Stock (NASDAQ:SLGL)

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

SLGL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SLGL Stock News Headlines

November 30, 2023 | finanznachrichten.de

Sol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

November 30, 2023 | finance.yahoo.com

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

December 8, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 28, 2023 | finance.yahoo.com

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

November 20, 2023 | finance.yahoo.com

Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?

November 9, 2023 | msn.com

Sol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48M

November 9, 2023 | finance.yahoo.com

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 31, 2023 | finance.yahoo.com

Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies

December 8, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

October 10, 2023 | finance.yahoo.com

Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?

August 30, 2023 | finance.yahoo.com

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 15, 2023 | msn.com

HC Wainwright & Co. Maintains Sol-Gel Technologies (SLGL) Buy Recommendation

August 11, 2023 | markets.businessinsider.com

Expert Ratings for Sol-Gel Technologies

August 10, 2023 | finance.yahoo.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates

August 10, 2023 | finance.yahoo.com

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 21, 2023 | finance.yahoo.com

Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Top Key Executive Moshe Arkin is the most upbeat insider, and their holdings increased by 15% last week

July 20, 2023 | nasdaq.com

Raymond James Maintains Sol-Gel Technologies (SLGL) Strong Buy Recommendation

June 6, 2023 | msn.com

Israel's Sol-Gel signs Canadian licensing deal for Twyneo, Eposolay

June 5, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Sol-Gel Technologies (SLGL)

June 2, 2023 | finance.yahoo.com

Shareholders in Sol-Gel Technologies (NASDAQ:SLGL) are in the red if they invested five years ago

May 12, 2023 | finanznachrichten.de

Sol-Gel Technologies Ltd.: Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023 | finance.yahoo.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2023 | finance.yahoo.com

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

April 22, 2023 | finance.yahoo.com

Companies Like Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Invest In Growth

April 13, 2023 | msn.com

HC Wainwright & Co. Reiterates Sol-Gel Technologies (SLGL) Buy Recommendation

April 12, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Sol-Gel Technologies (SLGL)

March 20, 2023 | finance.yahoo.com

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

See More Headlines

Receive SLGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sol-Gel Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/08/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SLGL
CUSIP: N/A
CIK: 1684693
Web: www.sol-gel.com
Phone: (728) 931-3433
Fax: 972-153-523044444
Employees: 55
Year Founded: 1997

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $9.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +566.3%
Consensus Rating: Strong Buy
Rating Score (0-4): 3.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,920,000.00
Net Margins: -1,665.41%
Pretax Margin: -1,665.41%
Return on Equity: -62.42%
Return on Assets: -55.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.09
Quick Ratio: 10.09

Sales & Book Value

Annual Sales: $1.21 million
Price / Sales: 23.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.83 per share
Price / Book: 0.66

Miscellaneous

Outstanding Shares: 23,129,000
Free Float: 7,746,000
Market Cap: $27.77 million
Optionable: Not Optionable
Beta: 1.38

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Alon Seri-Levy (Age 62)
Co-Founder, CEO & Director
Comp: $861k
Mr. Gilad Mamlok (Age 55)
Chief Financial Officer
Comp: $640k
Dr. Itzik Yosef (Age 47)
Chief Operating Officer
Comp: $316k
Mr. Moshe Arkin (Age 70)
Executive Chairman of the Board
Prof. David Avnir
Co-Founder
Ms. Tamar Fishman Jutkowitz (Age 47)
VP & General Counsel
Dr. Karine Neimann (Age 52)
VP of Projects & Planning and Chief Chemist

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SLGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Sol-Gel Technologies stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" SLGL shares.
View SLGL analyst ratings or view top-rated stocks.
What is Sol-Gel Technologies' stock price target for 2024?: 2 Wall Street analysts have issued 1-year price objectives for Sol-Gel Technologies' shares. Their SLGL share price targets range from $7.00 to $9.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 566.7% from the stock's current price.
View analysts price targets for SLGL or view top-rated stocks among Wall Street analysts.
How have SLGL shares performed in 2023?: Sol-Gel Technologies' stock was trading at $4.5599 at the beginning of 2023. Since then, SLGL stock has decreased by 73.7% and is now trading at $1.20.
View the best growth stocks for 2023 here.
When is Sol-Gel Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024.
View our SLGL earnings forecast.
How were Sol-Gel Technologies' earnings last quarter?: Sol-Gel Technologies Ltd. (NASDAQ:SLGL) released its quarterly earnings results on Thursday, November, 9th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. The company earned $0.21 million during the quarter, compared to the consensus estimate of $0.70 million. Sol-Gel Technologies had a negative net margin of 1,665.41% and a negative trailing twelve-month return on equity of 62.42%.

What other stocks do shareholders of Sol-Gel Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sol-Gel Technologies investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Flexion Therapeutics (FLXN), Iovance Biotherapeutics (IOVA), Marker Therapeutics (MRKR), Teva Pharmaceutical Industries (TEVA), Viking Therapeutics (VKTX), Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP).
When did Sol-Gel Technologies IPO?: (SLGL) raised $60 million in an initial public offering on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Jefferies and BMO Capital Markets served as the underwriters for the IPO and JMP Securities and Raymond James were co-managers.
Who are Sol-Gel Technologies' major shareholders?: Sol-Gel Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.23%), Yelin Lapidot Holdings Management Ltd. (0.99%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Sol-Gel Technologies?: Shares of SLGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SLGL) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial